These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20207566)

  • 1. [Innovative agreements with the pharmaceutical industry: "pay for performance"].
    Badia X; Prior M
    Farm Hosp; 2010; 34(2):53-5. PubMed ID: 20207566
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk-sharing agreements for innovative drugs: a new solution to old problems?
    de Pouvourville G
    Eur J Health Econ; 2006 Sep; 7(3):155-7. PubMed ID: 16912890
    [No Abstract]   [Full Text] [Related]  

  • 3. Where are we on "risk-sharing" agreements?
    Neumann PJ
    Value Health; 2013; 16(5):701-2. PubMed ID: 23947962
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel.
    Triki N; Ash N; Porath A; Birnbaum Y; Greenberg D; Hammerman A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):749-753. PubMed ID: 31825682
    [No Abstract]   [Full Text] [Related]  

  • 5. The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia.
    Darbà J; Ascanio M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):743-748. PubMed ID: 30821532
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success.
    Mahjoub R; Ødegaard F; Zaric GS
    Health Econ; 2018 Jan; 27(1):e15-e25. PubMed ID: 28627808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach.
    Antonanzas F; Juarez-Castello C; Rodriguez-Ibeas R
    Health Econ Policy Law; 2011 Jul; 6(3):391-403. PubMed ID: 21338542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Financial valuation of incentive arrangements in managed care contracts: a real options approach.
    Maurer RT
    J Health Care Finance; 2001; 28(1):39-60. PubMed ID: 11669292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.
    Garrison LP; Carlson JJ; Bajaj PS; Towse A; Neumann PJ; Sullivan SD; Westrich K; Dubois RW
    Am J Manag Care; 2015 Sep; 21(9):632-40. PubMed ID: 26618366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
    Hammerman A; Greenberg D
    Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk sharing agreements: what lessons from Italy?
    Garattini L; Casadei G
    Int J Technol Assess Health Care; 2011 Apr; 27(2):169-72. PubMed ID: 21429288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
    Zaric GS; Xie B
    Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.
    Neumann PJ; Chambers JD; Simon F; Meckley LM
    Health Aff (Millwood); 2011 Dec; 30(12):2329-37. PubMed ID: 22147861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.
    Zhang S; Doucette WR; Urmie JM; Xie Y; Brooks JM
    Res Social Adm Pharm; 2010 Jun; 6(2):121-9. PubMed ID: 20511111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry.
    Barros PP
    Health Econ; 2011 Apr; 20(4):461-70. PubMed ID: 21394816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managed care risk contracts and substance abuse treatment.
    Sturm R
    Inquiry; 2000; 37(2):219-25. PubMed ID: 10985114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory, Policy, and Operational Considerations for Outcomes-Based Risk-Sharing Agreements in the U.S. Market: Opportunities for Reform.
    Goodman C; Villarivera C; Gregor K; van Bavel J
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1174-1181. PubMed ID: 31535596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Italian risk-sharing agreements on drugs: are they worthwhile?
    Garattini L; Curto A; van de Vooren K
    Eur J Health Econ; 2015 Jan; 16(1):1-3. PubMed ID: 24728513
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.